Rationale Dopamine D3 receptors (D3R) may be important therapeutic targets for both drug abuse and dyskinesias in Parkinson's disease; however, little is known about their functional circuitry. Objectives We wished to determine if D3R antagonists SB-277011 and PG-01037 and D3R-preferring agonist 7-OH-DPAT are D3R selective in vivo. We further wished to characterize the response to D3R drugs using whole brain imaging to identify novel D3R circuitry. Methods We investigated D3R circuitry in rats using pharmacologic MRI and challenge with selective D3R antagonists and agonist at various doses to examine regional changes in cerebral blood volume (CBV). We compared regional activation patterns with D2R/D3R agonists, as well as with prior studies of mRNA expression and autoradiography. Results D3R antagonists induced positive CBV changes and D3R agonist negative CBV changes in brain regions including nucleus accumbens, infralimbic cortex, thalamus, interpeduncular region, hypothalamus, and hippocampus (strongest in subiculum). All D3R-preferring drugs showed markedly greater responses in nucleus accumbens than in caudate/putamen consistent with D3R selectivity and contrary to what was observed with D2R agonists. At high doses of D3R agonist, functional changes were differentiated across cortical laminae, with layer V-VI yielding positive CBV changes and layer IV yielding negative CBV changes. These results are not inconsistent with differential D1R and D3R innervation in these layers respectively showed previously using post-mortem techniques. Conclusions MRI provides a new tool for testing the in vivo selectivity of novel D3R dopaminergic ligands where radiolabels may not be available. Further, the functional D3R circuitry strongly involves hypothalamus and subiculum as well as the limbic striatum.
Introduction
Although a great deal is known about dopamine D1 and D2 receptor functions, the roles of the D3, D4, and D5 receptor sub-types are still being determined. The D3 receptor (D3R) was discovered by Sokoloff et al. (1990) who ascribed both autoreceptor-like function as well as postsynaptic activity to the D3Rs. That study, and subsequent work, demonstrated a circumscribed distribution of the D3 receptors in the brain occurring most densely in the islets of Calleja, the shell of the nucleus accumbens, and the olfactory tubercule in rodents (Khan et al. 1998; Sokoloff et al. 1990 ). This distribution is mirrored in primates (Khan et al. 1998 ). Unfortunately, due to the fact that highly selective D3R in vivo ligands have only recently appeared, studies on the distribution, behavior, and functional circuitry of these receptors is incomplete, something we chose to address in this study with two novel D3R-selective ligands, which have high D3R/D2R affinity in vitro.
There are only a few studies, in rodents, indicating what behavioral role D3 receptors have (Collins et al. 2007 (Collins et al. , 2009 ). Use of in vivo imaging can help to identify novel circuitry that may aid in determination of the substrates of behavioral effects. The highly limbic distribution of the D3 receptor has rendered it an important potential target for drugs targeted towards substance abuse, and there is evidence for the ability of D3R selective ligands to attenuate cocaine self-administration Newman et al. 2005; Vorel et al. 2002) . The D3 receptor is an important mediator of L-DOPA-induced dyskinesias in Parkinson's disease. There is compelling evidence of L-DOPA induction of ectopic D3 receptor expression in D1R-expressing medium spiny neurons in the striatum of parkinsonian rats and macaques (Bezard et al. 2003; Bordet et al. 1997) . Investigating D1R-D3R interactions is a possibility with phMRI techniques due to the opposite signs of the hemodynamic response to D1R and D3R agonists (Choi et al. 2006; Sanchez-Pernaute et al. 2007) .
Recent work has shown that DA function can be evaluated using MRI techniques in rats, monkeys, and humans (Chen et al. 1996 (Chen et al. , 2005 (Chen et al. , 1997 Choi et al. 2006; Jenkins et al. 2004; Marota et al. 2000; Risinger et al. 2005; Zhang et al. 2001) . Dopamine D1 receptor agonism leads to positive hemodynamic changes (Choi et al. 2006) , and D1R antagonism leads to negative hemodynamic changes (Choi et al. 2006; Marota et al. 2000) , while D2R/D3R agonism leads to negative hemodynamic changes (Chen et al. 2005; Choi et al. 2006) . Fewer studies have examined D3 receptors. A PET study showed decreased CBF in a number of brain regions in response to the D3R-preferring agonist pramipexole (Black et al. 2002) , while we showed decreased CBV in response to the D3R agonist 7-OH-DPAT (Choi et al. 2006 ). Neither of the latter studies examined the effects of D3R antagonism nor the effects of dose dependencies. More recently, the ligand 11 C-PHNO has been proposed as a D3R selective tracer based upon its displacement by selective D3R antagonists (Rabiner et al. 2009; Graff-Geurrero et al. 2009) .
In this work, we characterized the circuitry activated by D3R selective ligands in vivo in order to determine if additional brain regions related to D3R circuitry may come to light. Further, using dose dependencies, we wished to determine whether or not ligands with high in vitro affinity also manifest the same degree of D3R/D2R selectivity in vivo. We hypothesized that D3R agonism would lead to decreased CBV while antagonism would lead to increased CBV. We compared maps of functional changes in cerebral blood volume (fCBV) induced by these drugs with prior literature on the distribution of D3 receptors using mRNA expression levels as well as protein and ligand binding. A final goal of this paper was to determine if phMRI could be used as a tool for testing the in vivo selectivity of a novel D3R ligand. Since no radio-labeled D3R compounds have yet been verified, it is useful to be able to demonstrate that a novel ligand, with high in vitro D3R affinity, can also bind selectively to D3 receptors in vivo. This potentially provides a highly useful tool for evaluation of newly synthesized drugs where in vivo selectivity for the specific dopamine receptors may not yet be established and/or a radio-labeled version is not yet synthesized.
Materials and methods
Animals Adult, male Sprague-Dawley rats (250-300 g) were obtained from Charles River Laboratories (Willmington, MA, USA). Animals were anesthetized with 1.2% halothane in a 1:2 mixture of N 2 O and O 2 . The tail vein was catheterized for both contrast agent and drug administration. Body temperature was regulated using a circulating warm water blanket set to 37°C. Arterial blood gas sampling and blood pressure were measured by catheterization of the femoral artery in some instances, or using non-invasive blood pressure monitoring with an inflating tail cuffs (Kent Scientific, Torrington, CT, USA). All procedures were conducted in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals.
Contrast agent phMRI measurements were made using a dextran-coated superparamagnetic intravascular contrast agent of monocrystalline iron oxide nanoparticle (MION) (Shen et al. 1993) . MION was synthesized at the Martinos Center at Massachusetts General Hospital. It has recently been demonstrated that the iron oxide method or IRON (increased relaxation for optimized neuroimaging) greatly improves the contrast to noise ratio in both phMRI and traditional fMRI studies in animals (Chen et al. 2001) . The use of the IRON method allows the measurement of fCBV changes, a physiologically relevant parameter, and also allows for comparisons of data collected at different field strengths (Mandeville et al. 2004 ).
Pharmacological ligands
We used two different D3R antagonists. The first was a water-soluble agent N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-trans-but-2-enyl)-4-pyridine-2-enylbenzamide (PG-01037; Grundt et al. 2007) . This compound has an in vitro Ki for D3R 0.7 versus 375 nM for D2R for a D3R/D2R selectivity of 133.
A non-water-soluble agent (trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl) ethyl]cyclohexyl]-4-quinolininecarboxamide) (SB-277011) was obtained from GlaxoSmithKline laboratories (Reavill et al. 2000) . This compound has a reported selectivity of D3R/D2R of greater than 100. This compound has an elimination halflife of 2 h (Reavill et al. 2000) . Both agents were reported to cross the blood-brain barrier ). We used the common D3R agonist 7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) obtained from SIGMA-RBI (St. Louis, MO, USA). This compound has a reported in vitro selectivity for D3R/D2R of >100 (Levesque et al. 1992 ) and has behavioral effects persisting for about 1 h.
Although PG-01037 is relatively water soluble, we found that it precipitated when taken up in heparinized saline (2 units/ml). In non-heparinized saline, it was quite soluble at the doses used, and all studies were performed after i.v. administration of PG-01037 in saline. The SB-277011 is not water soluble, and thus we administered this compound as a slurry in methylcellulose at a single i.p. dose of 10 mg/kg. The 7-OH-DPAT was administered i.v. in heparinized saline.
Pharmacological MRI (phMRI) phMRI images were acquired from a 9.4T Bruker (Billerica, MA, USA) console with a Magnex (Oxford, UK) magnet, for the 7-OH-DPAT and PG-01037 studies. The SB-277011 data were acquired from a 4.7-T magnet with a Bruker console and an Oxford magnet. For the SB-277011 data, we collected 8×1-mm slices with in-plane resolution of 0.234×0.234 mm. For all the other studies, we followed the same protocol as published earlier for phMRI studies (Chen et al. 2005; Choi et al. 2006) . Briefly, a conventional gradient echo sequence with TR/TE of 500/7.6 ms was used to acquire phMRI data. Eighteen contiguous coronal slices were obtained for each time point with in-plane spatial resolution of 0.2×0.2 mm 2 and a 0.75-mm slice thickness. The temporal resolution was 64 s per image set. We acquired four pre-MION baseline images followed by at least 25 post-MION images for the pre-drug baseline. Then, drugs were injected in the magnet during continuous imaging.
The use of the IRON technique allows for comparisons at different field strengths since the change in CBV (fCBV) measured using this technique are independent of field strength as we demonstrated previously using cocaine and methylphenidate stimulations (Mandeville et al. 2004 ). Images were acquired serially without interruption for over 2 h. A minimum of four baseline points were acquired before the injection of MION contrast agent, and a minimum of 25 post-contrast baseline points were acquired before the administration of drugs.
To assess the effects of the D3R antagonists and agonist on blood pressure, measurements (mmHg) were made using either direct arterial sampling of pressure or a non-invasive measurement from the tail (Kent Scientific, CT, USA).
Study protocol We performed the following studies using the drugs; PG-01037 was studied at five different doses: 1 mg/kg, n=4; 2 mg/kg, n=5; 3 mg/kg, n=7; 5 mg/kg n=7; and 6 mg/kg, n=4. We chose this dose range since initial attempts with 1 mg/kg and less yielded little response and we did not wish to exceed 10 mg/kg based upon the i.p. doses of this drug that had been tried behaviorally (Collins et al. 2007) . Each study was run separately with i.v. injections of compound. SB-277011 was very insoluble and hence was studied at one dose: 10 mg/kgi.p. 7-OH-DPAT was run at five doses running from the lower limit of typical behavioral studies of 0.1 mg/kg to a dose over 10 times higher therefore we used: 0.1 mg/kg, n=4; 0.25 mg/kg, n=6; 0.5 mg/kg, n=4; 1.5 mg/kg, n=4; and 3.0 mg/kg n=3. This drug was injected i.v. In addition, two other experiments were performed to determine the relative affinity of the agonist versus the antagonist in vivo, and to ascertain that the novel ligand (PG-01037) was competing for D3R receptors with a well-studied D3R agonist (7-OH-DPAT). We first injected the D3R antagonist PG-01037 (2 mg/kg) followed 30 min later by 0.2 mg/kg of 7-OH-DPAT (n=5 animals). We then performed the reverse experiment in a separate group where we injected 7-OH-DPAT first followed 30 min later by PG-01037 (n=5). These time points represent points where peak CBV responses are seen to the two drugs.
Data analysis
Image co-registration To facilitate comparisons between different groups of animals, all images were registered onto the same standard brain template for subsequent averaging across animals. The data were resliced to a thickness of 0.5 mm. Since motion during a functional scan was not a consideration due to anesthesia and the use of a head holder, registration parameters were determined for each functional scan using a single full-brain volume that was the average of all time points after MION injection but prior to drug injection. These registration parameters were then applied to all time points in the functional data set. Registration between the functional image set and the standard template was performed by adjusting 12 registration variables in a standard affine transformation as generally applied in human studies. The template images were consistent with the stereotactic coordinate system atlas from Paxinos (Paxinos and Watson 1986) . Then, regions of interest (ROIs) can be drawn for any of the regions defined in the atlas. The regions we chose to analyze were those that are described to be enriched in D3 receptors as well as others, such as the caudate/putamen, that allow for assessment of the selectivity of D3R/D2R (defined in Tables 1 and 2 ). Further, we also analyzed a few other regions little described with respect to D3R, such as the interpeduncular region that turned out to have quite large CBV changes. We further sub-divided the caudate-putamen into two regions: anteromedial and dorsolateral. Although there are no exact anatomic borders, the former is usually considered limbic striatum and has different patterns of cortical innervation than the latter which has more motor innervation.
Functional analysis Maps of percent CBV changes were obtained by converting signal intensity changes to ΔR2* on a pixel by pixel basis (Chen et al. 2001 ) and assuming a linear relationship between R2* relaxivity and blood volume. The fCBV was defined as a percent change from baseline (ΔCBV) and then averaged over a given time interval as in Eq. 1 below where A=30 min after D3R drug injection. We chose 30 min since it represents an integral encompassing the peak response to all three of the drugs studied. Statistical maps were made by fitting the CBV time course to a gamma function using a general linear model. Maps of the difference in average ΔCBV were made for experiments where we injected either a D3R agonist followed by a D3R antagonist or vice versa. For these experiments, we used the average ΔCBV of the initial drug alone from time point 0 to A=30 min and then used Eqs. 2 and 3 below to calculate the percent change in the average ΔCBV from time A (where either D3R agonist or antagonist is injected) to B=50 min following the second drug injection of agonist or antagonist.
Statistics Between group comparisons were made using a one-way ANOVA with dose for each brain region using the integrated CBV as in Eqs. 1, 2, and 3 above, with post hoc tests being performed using a Tukey HSD to correct for multiple comparisons when the omnibus F test was significant. Errors reported are standard errors of the mean. We note that the maps generated from the general linear model are for display purposes; the actual fCBV values (unsmoothed) were used for the between group comparisons.
Results

D3R selective antagonist PG-01037
We studied two different D3R selective antagonists PG-01037 and SB-277011. PG-01037 is a water-soluble antagonist with nanomolar in vitro affinity for the D3R ). PG-01037 had no significant effects on blood pressure (mmHg) at any time points or doses: baseline pressure=102.6±14.5; 1 min post-drug=97.9±12.9 (p<0.2); 5 min=100.1±15.3 (p<0.3); 30 min=100.9±17.1 (p<0.6). Shown in Fig. 1a are the major regions of interest used in the analysis registered to the template brain to which all the studies were aligned-the ROIs are explicitly defined in Table 1 . A map of significant changes in fCBV induced by 2 mg/kg of PG-01037 averaged from ten rats is shown in Fig. 1b . Prominent positive fCBV changes are induced in a number of different brain regions including the accumbens, thalamus, and subiculum (CA1 region of Ammon's horn). In order to see the activation in the ventral striatum and accumbens more accurately, Fig. 2a shows three slices from the region of the nucleus accumbens (NAc) with an overlay of a registered rat brain outline including the accumbens core and shell. There are larger fCBV changes in the shell of the accumbens compared with the core or the caudate/putamen (CPu). Richtand et al. (1995) using quantitative values for mRNA expression in various brain regions (Fig. 2c) . By chance, the absolute magnitude of the units chosen for both the binding assays and the mRNA expression match the fCBV changes closely, thus allowing for direct comparisons using the same ordinate.
A full description of the fCBV changes observed for PG-01037 for more brain regions and at the two doses is shown in Table 1 . We studied doses between 1 and 6 mg/kg i.v. In this dose range, in most brain regions, there was more variability between animals than between doses. We chose not to further analyze the 1 mg/kg since two of the animals showed no changes in fCBV. Therefore, in Table 1 , we averaged the results of 2-3 mg/kg and the results from 5-6 mg/kg. Even binning the data as such image to which all the brains were registered. The slices occur at 0.5-mm intervals, and the distances from bregma are indicated in white numbers. b Average map of statistically significant changes in fCBV induced by 2.6 mg/kg of PG-01037 (n=13) using a fit to a general linear model. Numerous brain regions show a strong response, but there is a much larger response in the shell of the accumbens than in the caudate/putamen indicating the high D3 selectivity of this compound yielded small dose effects for this compound. The brain regions that showed a significant effect of dose were cingulate, hypothalamus, posterior-lateral CPu, and lateral frontoparietal cortex. Although most of the brain regions did not show a significant dose effect, we were able to segregate the doses using linear discriminant analysis (Fig. 2d) , which showed that the 2-3 and the 5-6 mg/kg segregated along one axis. Therefore, we averaged together the two dose ranges for presentation in Table 1 .
D3R selective antagonist SB-277011
The drug is insoluble in water, so we injected it i.p. in methylcellulose. Our data show that SB-277011 produces a large increase in fCBV in the medial prefrontal cortex (MPFCx), NAc, and thalamus for a dose of 10 mg/kgi.p. (Fig. 3a) . The time course for these changes shows a return to baseline in about 40 min (Fig. 3b) . Unlike for PG-01037, the largest change is induced in the MPFCx and infralimbic cortex. Similar to PG-01037, there is large activation in the NAc and thalamus and much less in CPu.
D3R-preferring agonist 7-OH-DPAT
We used 7-OH-DPAT since this compound is the most commonly used D3R agonist. For 7-OH-DPAT, there was a small transient effect on blood pressure that was significant as follows (doses 0.1-0.5 mg/kg): baseline pressure=102.3± 18.8; 1 min=94.5±15.4 (p<0.01); 5 min=94.9±17.1 (p< 0.01); 30 min=98.0±16.5 (p<0.06). At doses higher than 1.5 mg/kg, there was no drop in blood pressure and no significant change as a function of time-perhaps because of the balance between D3R and D1R vascular effects (vide infra). Figure 4 shows maps of fCBV changes induced by an acute dose of 0.1 mg/kg 7-OH-DPAT as well as a map of the fCBV changes induced by 0.5 mg/kg. Since the number of animals was different for the two doses, we used maps of the fCBV since CBV is independent of n. Large changes in fCBV are induced in the NAc and thalamus with smaller, but (1998) . Just by sheer chance, the absolute magnitude of the three metrics are quite comparable in the NAc allowing for direct comparisons. The overall pattern indicates good D3 selectivity for the PG-01037. d Although most brain regions did not show a significant effect of dose using ANOVA analysis, the doses can be separated using the averaged CBV values over 40 min across brain regions using linear discriminant analysis. The two discriminant functions are plotted with the percent of variance in the data they explained. Function 1 was significant by Wilk's lamba (p=0.013) whereas function 2 was not (p=0.47) robust changes in the MPFCx and striatum. Shown in Fig. 5 are regional and temporal comparisons of receptor activity between this D3R agonist and a D2R selective agonist (norpropylapomorphine). The CBV and autoradiographic data were taken from Choi et al. (2006) . Also shown in Fig. 5a are data from a single animal with a registered overlay from a rat brain atlas (Paxinos and Watson 1986) . Alongside the fCBV map is a map of autoradiographically labeled 7-OH-DPAT taken from a paper published by Neisewander et al. (2004) that is shown side-by-side with the CBV map for comparative purposes. It can be seen that there is a much less activation in the CPu (shown in the red outline) than for the accumbens illustrating the selectivity of the 7-OH-DPAT for D3 receptors. The time courses for the fCBV changes are also shown in Fig. 5 as well as the absolute value of the average fCBV changes induced between 0 and 30 min, again compared with data from Bancroft et al. (1998) Richtand et al. (1995) using quantitative values for mRNA expression in various brain regions. The time to return to baseline is shorter in the cingulate and thalamus. The full-width half maximum (FWHM) of the average fCBV curves is 22.8, 13.9, and 9.6 min respectively for the accumbens, thalamus, and cingulate.
Unlike for the D3R antagonist, there is a strong dose dependence for most brain regions with 7-OH-DPAT (see Table 2 ). Most surprising is that higher doses of 7-OH-DPAT produce a cortical response that is differentiated by laminae with positive fCBV changes in layers V and VI of the cortex, and negative fCBV changes in layers III and IV of cortex. These effects are shown in Fig. 6 along with maps of mRNA expression and ligand binding for D3 receptors (in layer IV) and mRNA expression levels for D1 receptors (in layers V and VI) and taken from Gurevich and Joyce (2000) . The fCBV changes induced in these layers is shown in Fig. 6c, d showing the clear laminar dichotomy between the positive and negative fCBV changes. Laminae also exhibit different temporal responses: the positive fCBV change in layer V-VI has a FWHM of 7 min and the negative change in layer IV has a FWHM of 23 min (Fig. 6c) . We studied an additional three animals using 3 mg/kg of 7-OH-DPAT, and the response produced was essentially identical to that at 1.5 mg/kg with regards to the layer specificities noted (see Fig. 7 ). Making a map of the early peak response versus the later peak response confirms the layer specificity. Since layers III-IV cover about Fig. 3 Maps of D3 antagonist SB-277011A. a Map of statistically significant changes in fCBV after administration of 10 mg/kg i.p. of the D3 antagonist SB-277011A. There is a large response in NAc and little in the CPu. In contrast to the PG-01037, the largest response is in the medial prefrontal cortex. b Averaged fCBV response after i.p. administration of SB-277011A (n=7). The signal has returned to baseline after approximately 40 min Fig. 4 Maps of responses to two doses of the D3 agonist 7-OH-DPAT. a Averaged map of statistically significant fCBV changes to 0.1 mg/kg of 7-OH-DPAT (n=4). The largest responses are noted in the NAc and the anteromedial CPu. b Averaged map of statistically significant fCBV changes to 0.5 mg/kg of 7-OH-DPAT (n=5). There is a greater response in numerous regions of the brain reflecting the large dose dependence noted with this drug compared with the D3 antagonist 0.55 mm and layers V-VI cover about 1.1 mm (Paxinos and Watson 1986) , our spatial resolution yields about 2.75 pixels for layers III-IV and 5.4 pixels for layers V-VI. There is a clear inflection point visible going from negative fCBV in layers III-IV to positive fCBV in layers V-VI with the CBV zero in between (Fig. 6d) . Given that two pixels are the minimum to adequately define a region, our resolution is adequate to discriminate between these two sets of layers.
Comparisons of D3R selectivity for the drugs using MRI Since D3R expression levels in normal animals are much stronger in the shell of the accumbens (NAc) than in the caudate/putamen (CPu), it is appropriate to use some sort of ratio of the induced fCBV changes in the latter two regions as a metric for the in vivo selectivity of each drug. For D1 and D2 receptor ligands that we have assessed previously, this ratio is quite close to 1 (Chen et al. 2005; Choi et al. 2006) , which is consistent with the known distributions of the D1 and D2 receptors. For the purposes of this manuscript, we chose a simple ratio of the ΔfCBV in NAc/CP. The higher the ratio, the greater the in vivo selectivity for D3R over D2R. The ratio of the NAc/CPu for 7-OH-DPAT at doses of 0.2 and 0.5 mg/kg are 1.9 or greater versus 2.5 for PG-01037 at a dose of 2-3 mg/kg (p<0.01) demonstrating the higher selectivity of the latter ligand in this dose range. For the SB-277011, the ratio was also about 2.4. These ratios compare with those determined from our prior work where at doses of 2 mg/kg both quinpirole (Chen et al. 2010 ) and norpropylapomorphine (Choi et al. 2006) show ratios of close to 1 as shown comparing all the D2R and D3R drugs in Fig. 8 . Comparing the NAc/CPu ratio for the D2R and D3R drugs using a one-way ANOVA with a Tukey HSD correction showed that all the D3R ligands were significantly different from either quinpirole or norpropylapomorphine with p<0.001, and none of the D2R ligands were significantly different from one another (p=0.997).
Combined studies of D3R agonist and antagonist
We studied the effects of pre-and post-treatment with D3R antagonist and D3R agonist of each drug together. We performed a continuous imaging experiment where administration of 2 mg/kg PG-01037 was followed 30 min later by 0.2 mg/kg of 7-OH-DPAT. The 7-OH-DPAT leads to immediate reversal of the positive fCBV changes induced by the D3R antagonist in most brain regions. A subtraction map of the effects of PG-01037 minus those of 7-OH-DPAT is shown in Fig. 9a . Since the CBV effects of the antagonist are positive and those of the agonist are negative (Fig. 9b) , the subtraction map shows positive values. This map thus represents those regions that are most strongly targeted by both drugs (i.e., a conjunction map). As shown for the individual drugs, the differential response exhibits a strong gradient from NAc to CPu and very large values in the hypothalamus and interpeduncular region. Performing the experiments in the reverse manner with 0.2 mg of 7-OH-DPAT followed by 2 mg/kg of PG-01037 showed almost a complete blockade of the positive fCBV changes induced by the D3R antagonist (Fig. 9c) . We also made conjunction maps of the combined effects of 2 mg/kg PG-01037 and 0.2 mg/kg of 7-OH-DPAT. The maps look essentially identical to that in Fig. 9a , again demonstrating the higher in vivo occupancy with 0.2 mg/kg 7-OH-DPAT than for 2 mg/kg PG-01037.
Discussion
Signs of the hemodynamic changes and D3R circuitry
These results indicate the utility of in vivo, non-invasive imaging methods for the determination of the receptor selectivity of dopaminergic drugs. Both of the two highly selective D3R antagonists studied led to increased fCBV in brain regions that are largely consistent with the limbic D3R circuitry and SB-277011 is reported to reduce cocaine-seeking behaviors in rats (Vorel et al. (2000) showing the layer specificity of D1R mRNA expression in layers V-VI of cortex. b Averaged map (n=5) of CBV changes induced by 1.5 mg/kg of 7-OH-DPAT. Note the large activation in basal ganglia and the negative D3-like CBV in layers III-IV and the positive D1-like CBV changes in layers V-VI. c Averaged CBV time course for activation in layers IV and V for 1.5 mg/kg 7-OH-DPAT. d Plot of the fCBV values as a function of distance normal to the cortical surface. The values represent the averages over a 1-mm slice interval from bregma (+1.2-0.2) and the identification of the layers follows that drawn in the Paxinos and Watson atlas (1986) 2002). Our prior studies show that D1R/D5R agonism produces positive BOLD or CBV changes, whereas D2R/ D3R agonism produces negative BOLD or CBV changes (Chen et al. 2005; Choi et al. 2006) . Thus, the increased CBV produced by D3R antagonism is consistent with these observations. We further found that D3 receptors were located in astrocytes associated with the endothelium and therefore can provide a means for coupling changes in dopamine levels with vasoconstriction (Choi et al. 2006 ). D1 and D5 receptors are present on microvessels and capillaries and are capable of converting dopamine release into positive CBV changes (Choi et al. 2006) .
Our results for the pattern of activity with both the antagonist and agonist were similar to both the mRNA distributions of the D3 receptor determined by Richtand et al. (1995) as well as the binding of drugs such as PD-128907 and 7-OH-DPAT (Bancroft et al. 1998 ). There are some discrepancies noted between the binding data and the mRNA data. In particular, the mRNA expression is high in both hypothalamus and hippocampus similar to the phMRI data. Unfortunately, there are not enough brain regions reported in the literature to obtain a reliable discrimination to whether the fCBV data correspond better to the ligand binding data or the mRNA expression levels. We observed robust activation in the subiculum region of the hippocampus (CA1 field of Ammon's horn), which also includes some dentate gyrus activation as well. This specific selectivity within the hippocampus for D3 receptors has not been described previously, but the result is consistent with the large CBV changes within infralimbic cortex ( Fig. 1; Table 1 ) and the strong connectivity of infralimbic cortex with the subiculum (Swanson 1981) .
We found the interpeduncular region to be strongly affected by the D3R drugs (see Fig. 8 ). The sole reference to this region that we could find was a comparative study where the interpeduncular region was found to bind a relatively non-selective D3R antagonist in rabbits (Levant 1998) . A recent paper examined the modulation of amphetamine-induced limbic correlations using D3R antagonism and claimed there was negative modulation of ventral tegmental area (VTA) by D3R antagonism (Schwarz et al. 2007 ). The VTA and the interpeduncular region are hard to separate; therefore, it is possible that what we have labeled interpeduncular could also include some VTA as well (the converse is also true).
The islets of Calleja are the region of the brain in both primates and rodents with the highest density of D3R receptors; however, they are quite small and spatially dispersed. The size of the largest segments of the islets of Calleja (where individual segments can be up to 0.15×1× 0.2 mm) is on the order of our average voxel size (0.21× 0.21×0.75 mm). Nonetheless, there are very strong changes in fCBV in the region of the islet of Calleja that are not inconsistent with activation of this structure. We have reported this area in Table 1 with the caveat that this region also includes some septum and accumbens.
The two antagonists led to no significant blood pressure changes. The small decrease in blood pressure induced by Fig. 7 Maps of the response to 3 mg/kg of 7-OH-DPAT. We fit the data to an early response and a late response as shown in the images. a The early peak shows the positive fCBV in layers V-VI. b The later peak shows the negative fCBV cortical response in layers IV. c The combined response map (response to both peaks) is shown. d The fCBV time courses in layers IV and V-VI are shown, indicating a similar pattern to that seen in Fig. 6 for 1 .5 mg/kg 7-OH-DPAT. For comparative purposes, the shell of the nucleus accumbens is also shown 7-OH-DPAT (about 8 mmHg at peak) would not be expected to cause any changes that would result in alterations in cerebrovascular autoregulation (Zaharchuk et al. 1999 ).
Selectivity of D3R over D2R-utility of phMRI
The relative selectivity for D3R over D2R for each ligand can be inferred in a functional manner in these studies based upon the correlations between the regional selectivity of the fCBV data and data on the regional expression of D3 receptors using mRNA expression levels and/or autoradiography. Since D2 receptors show relatively equal density in caudate/putamen and nucleus accumbens (MeadorWoodruff 1994) , but D3 receptors have very low density in CPu, we chose a simple metric to represent this fact by comparing the ratio of fCBV values in the nucleus accumbens over caudate/putamen. The D3R agonist 7-OH-DPAT binds to D3 receptors with subnanomolar affinity and has been reported to show a selectivity of 100-fold for D3R over D2 receptors in vitro; however, there is some controversy over its in vivo selectivity based upon behavioral measures (Baker et al. 1999 ). Levant and colleagues found that stimulation of D2R with 7-OH-DPAT only occurs at doses above about 0.3 mg/kg (Levant et al. 1996) . We found that 7-OH-DPAT produced a ratio of about 2 for the changes in fCBV in NAc/CPu at all the doses tested even up to 1.5 mg/kg (see Table 2 ). This accords with behavioral studies showing inhibition of locomotor activity in wild-type mice at low doses, but no effects in D3R-knockout mice (Pritchard et al. 2003) . In human brain, the binding of [ 3 H]7-OH-DPAT showed a ratio of 2.4 for NAc/DLCPu (Herroelen et al. 1994) . These data suggest that in vivo this ligand has some selectivity for D3R over D2R, although the activation seen in CPu would suggest some D2R activity consistent with prior behavioral studies in D2R knockout mice showing that 7-OH-DPAT is still half as effective at inhibition of locomotor activity as it is in wild-type mice (Boulay et al. 1999) . The two antagonists, at the doses administered, show more selectivity than the agonist producing ratios of NAc/CPu of 2.4 and 2.5, respectively, for the SB-277011 and PG-01037 in agreement with the greater than 100-fold D3R/D2R selectivity seen in binding assays in vitro Reavill et al. 2000) . It should be pointed out that although the in vitro affinities are much higher for D3R than D2R, in vivo, the much higher D2 receptor density (B max ) will lead to considerable occupancy and activation of these receptors as well as the D3 receptors.
The utility of the phMRI in characterization of the in vivo specificity of the novel D3R ligands shows great promise. The maps generated of the PG-01037 are quite consonant with D3 receptor circuitry (see Figs. 1, 2, and 8) and not with D2R circuitry given the much smaller response in the caudate/putamen for the D3R drugs (at any dose) compared with that observed for D2R/D3R drugs such as norpropylapomorphine (Fig. 5) and quinpirole or eticlopride (Chen et al. 2005 (Chen et al. , 2010 Choi et al. 2006) . Therefore, it is likely that these types of experiments will prove invaluable for characterization of novel ligands without the necessity of creating radio-labeled ligands, a task that, thus far, has proved difficult for D3 receptors. Thus, more studies are necessary to confirm its D3R affinities. Balancing this potential is the fact that it is still difficult to convert a hemodynamic metric into a quantitative value representing receptor affinity-something that is still the provenance of radiolabeled ligands. Nevertheless, when combined with the in vitro binding assays, maps of the type generated here provide a compelling case for in vivo D3R selectivity of the ligands studied here.
The ability of 7-OH-DPAT at 0.2 mg/kg to block the fCBV effects of PG-01037 at 2 mg/kg (and the inability of PG-01037 to block 7-OH-DPAT) suggests that there is higher occupancy of the former at the dose administered. This fact is commensurate with the observation that large i.p. doses of PG-01037 are needed to obtain D3R-specific behaviors (Collins et al. 2007 ). However, the fact that we see robust activation at 2 mg/kg i.v. (much lower than the i.p. doses) suggests that peripheral Fig. 8 Plot of the ratio of fCBV in the nucleus accumbens (NAc) over that in the dorsolateral caudate/putamen (CPu) for the drugs studied here PG-01037; SB-277011; 7-OH-DPAT. Since the density of D3 receptors is much higher in the NAc compared with the CPu, this ratio should be greater than 1 for a drug showing D3 selectivity. As a comparison the ratio for the D2/D3 agonists, quinpirole (Quin) and norpropylapomorphine (NAPO) are also shown recalculated from data we published previously (Choi et al. 2006; Chen et al. 2010) . Comparisons between the D2 and D3 drugs showed that the differences were significant for all D2 versus D3 comparisons (all p values <0.001) metabolism is an important determinant of the final brain concentrations obtained. Pharmacokinetic studies in rats are underway for PG-01037 to specifically address this subject. Large discrepancies (a factor of 10) between the effective doses for i.p. and i.v. administration are also seen for drugs such as cocaine and methylphenidate.
Prior studies using the potential D3R-selective ligand 11 C-PHNO have recently been reported (Rabiner et al. 2009; Graff-Geurrero et al. 2009 ). Rabiner et al. found that 11 C-PHNO could be blocked using the same D3R antagonist we studied SB-277011, suggesting D3R selectivity. This ligand appears to have its highest binding in the globus pallidus and nigral region and does not seem to manifest higher binding in accumbens compared with caudate/putamen. Thus, some caution is warranted in unequivocally stating its D3R selectivity.
Cortical laminae specificity of D3R agonism Prior behavioral studies in rats indicated that low doses of 7-OH-DPAT inhibit locomotor activity, whereas high doses potentiate it (Ahlenius and Salmi 1994; Svensson et al. 1994) , suggesting either two classes of D3 receptor (preand post-synaptic) or stimulation of other receptors-such as D1.
The latter points lead to perhaps one of the more exciting findings of this study-that is the ability to detect signals of opposite signs in the cortical layers using very high doses (≥1.5 mg/kg) of the D3R agonist 7-OH-DPAT. Our prior study showed that D1R agonists increase fCBV, while D2R/D3R agonists decrease fCBV (Chen et al. 2005; Choi et al. 2006) . Using moderately high spatial resolution (0.21×0.21×0.75 mm), we found that cortical layers V-VI showed positive fCBV changes while layers III-IV showed negative fCBV changes. These results are consistent with histological data obtained by Gurevich and Joyce (2000) . In that paper, they showed that D3 receptors, as measured by both ligand binding or mRNA expression, were found in layer IV of barrel cortex. Further, they found that none of the other DA receptors, including dopamine D2 receptors, were expressed in layer IV. Conversely, there was high expression of D1 receptors in infragranular Fig. 9 Interactions of D3 agonist and antagonist using serial drug injections. a Subtraction map of CBV changes induced by 3 mg/kg of PG-01037 in the first 30 min followed by 0.2 mg/kg of 7-OH-DPAT in the following 30 min. Since the subtraction is a positive CBV change minus a negative CBV change, the result is positive and is essentially a conjunction map of the two drugs. The strongest effects were seen in the NAc, medial hypothalamus, and interpeduncular regions. b Plot of the averaged fCBV time course from the NAc. The agonist immediately turns off the antagonist. c A bar graph of the brain regional effects of the antagonist preceded by the agonist (n=5). The agonist at this dose (0.2 mg/kg) blocks the antagonist (3 mg/kg) in most brain regions. d A bar graph of the regional effects of the antagonist first (3 mg/kg) upon the agonist (0.2 mg/kg) (n=5). At this dose, the antagonist does not block the effects of the agonist in most brain regions. ***p<0.001; **p <0.01; *p<0.05. Cing anterior cingulate, VMH ventromedial hypothalamus, VMStr medial caudate/ putamen, Shell shell of the NAc, LFPCx lateral frontoparietal cortex regions-especially in layer VIb. Similar results were found in adult rats where neurons containing D1R mRNA were most abundant in layer VIb-but were also found in layers VIa and V (Gaspar et al. 1995) . These findings are thus consistent with the location of positive fCBV changes we see in layers V-VI. Interestingly, the time courses (FWHM) of these fCBV changes are different and can be discriminated by time course (see Figs. 6 and 7) , again suggesting that they arise from different neuronal populations. Obviously, given the high dose necessary to obtain the positive fCBV changes, the possibility of some D2R agonism, or poly-synaptic stimulation of gabaergic receptors cannot be eliminated in assigning the negative fCBV changes to D3 receptors. The stimulation of D1R activity with a D3R agonist is not unprecedented-administration of 7-OH-DPAT led to positive fCBV changes in Parkinsonian monkeys with dyskinesia compared with the negative fCBV changes induced in Parkinsonian monkeys without dyskinesias or in normal controls (Sanchez-Pernaute et al. 2007 ). These observations are consistent with D3R upregulation in motor striatum signaling through D1R pathways on neurons that co-express D3R (Schwartz et al. 1998 ) and further support strong interactions between D1 and D3 receptors.
Although hemodynamic metrics can be considered to be an indirect reflection of receptor binding, and are often difficult to interpret, they also represent a transduction mechanism that is sensitive to synaptic signaling processes (Attwell and Iadecola 2002) in addition to the direct effects of neurotransmitters such as dopamine. We found that D3 receptors are heavily expressed in astrocytes-and lead to vasoconstriction-but unlike D1 and D5 receptors were not present on capillaries or microvessels (Choi et al. 2006 ). The CBV changes we observed are entirely consistent with the effects of D1, D2, and D3 receptors upon adenylate cyclase activity and G-protein coupling. Therefore, they likely represent a level of sensitivity that should prove quite useful for examination of any number of dopaminergic ligands. Further, the ability to determine whole brain activity, as well as pharmacodynamic profiles, will enable much more detailed characterization of novel dopaminergic ligands where radiolabled versions do not exist. In this regard, PET and phMRI can be regarded as complementary techniques.
